模拟M72/AS01E疫苗接种和卡介苗复种对健康和经济的影响:南非的估计
该研究使用按年龄分层的结核病传播模型,校准南非流行病学数据,模拟M72/AS01E疫苗2030—2050年和卡介苗复种2025—2050年的接种情景。结果显示M72/AS01E可能比卡介苗复种影响更大,到2050年避免约80%更多的病例和死亡;两种疫苗在一系列疫苗特征和接种策略下从卫生系统和社会角度均具有成本效果或成本节约。
要点
- M72/AS01E接种可能比卡介苗复种影响更大,到2050年避免约80%更多的病例和死亡。
- 两种疫苗在一系列疫苗特征和接种策略下从卫生系统和社会角度均具有成本效果或成本节约。
- 将卡介苗复种扩展至接受抗逆转录病毒治疗的HIV感染者使健康影响增加约15%,但卫生系统成本增加约70%。
核心结论
- 结果表明,在南非接种M72/AS01E疫苗或卡介苗复种可能具有成本效果,但估计的影响和成本因疫苗特征和接种策略选择的不确定性而存在相当大的不确定性。
研究设计与样本
- 使用按年龄分层的结核病传播模型,校准南非流行病学数据,模拟M72/AS01E疫苗接种2030—2050年情景和卡介苗复种2025—2050年情景,探索一系列产品特征和接种策略,从卫生系统和社会角度计算结核病病例和死亡减少以及成本和成本效果。
主要发现
- M72/AS01E接种可能比卡介苗复种影响更大,到2050年避免约80%更多的病例和死亡。
- 两种疫苗在一系列疫苗特征和接种策略下从卫生系统和社 会角度均具有成本效果或成本节约(与无新疫苗相比)。
- M72/AS01E的影响取决于假设的疫苗在未感染个体中的效力。
- 将卡介苗复种扩展至接受抗逆转录病毒治疗的HIV感染者使健康影响增加约15%,但卫生系统成本增加约70%。
局限性
- 估计的影响和成本因疫苗特征和接种策略选择的不确定性而存在相当大的不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis remains a major public health problem in South Africa, with an estimated 300,000 cases and 55,000 deaths in 2021. New tuberculosis vaccines could play an important role in reducing this burden. Phase IIb trials have suggested efficacy of the M72/AS01E vaccine candidate and BCG-revaccination. The potential population impact of these vaccines is unknown. METHODS: We used an age-stratified transmission model of tuberculosis, calibrated to epidemiological data from South Africa, to estimate the potential health and economic impact of M72/AS01E vaccination and BCG-revaccination. We simulated M72/AS01E vaccination scenarios over the period 2030-2050 and BCG-revaccination scenarios over the period 2025-2050. We explored a range of product characteristics and delivery strategies. We calculated reductions in tuberculosis cases and deaths and costs and cost-effectiveness from health-system and societal perspectives. FINDINGS: M72/AS01E vaccination may have a larger impact than BCG-revaccination, averting approximately 80% more cases and deaths by 2050. Both vaccines were found to be cost-effective or cost saving (compared to no new vaccine) across a range of vaccine characteristics and delivery strategies from both the health system and societal perspective. The impact of M72/AS01E is dependent on the assumed efficacy of the vaccine in uninfected individuals. Extending BCG-revaccination to HIV-infected individuals on ART increased health impact by approximately 15%, but increased health system costs by approximately 70%. INTERPRETATION: Our results show that M72/AS01E vaccination or BCG-revaccination could be cost-effective in South Africa. However, there is considerable uncertainty in the estimated impact and costs due to uncertainty in vaccine characteristics and the choice of delivery strategy. FUNDING: This work was funded by the Bill & Melinda Gates Foundation (INV-001754). This work used the Cirrus UK National Tier-2 HPC Service at EPCC (https://www.cirrus.ac.uk) funded by the University of Edinburgh and EPSRC (EP/P020267/1).
引用
- Sumner T, Clark RA, Mukandavire C, et al. Modelling the health and economic impacts ofM72/AS01E vaccination and BCG-revaccination: Estimates for South Africa. Vaccine. 2024. PMID: 38307747. doi:10.1016/j.vaccine.2024.01.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。